<?xml version='1.0' encoding='utf-8'?>
<document id="25175364"><sentence text="Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation."><entity charOffset="43-54" id="DDI-PubMed.25175364.s1.e0" text="vincristine" /><entity charOffset="60-65" id="DDI-PubMed.25175364.s1.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.25175364.s1.e0" e2="DDI-PubMed.25175364.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25175364.s1.e0" e2="DDI-PubMed.25175364.s1.e1" /></sentence><sentence text="The aim of the current work was to perform a clinical trial simulation (CTS) analysis to optimize a drug-drug interaction (DDI) study of vincristine in children who also received azole antifungals, taking into account challenges of conducting clinical trials in this population, and, to provide a motivating example of the application of CTS in the design of pediatric oncology clinical trials"><entity charOffset="137-148" id="DDI-PubMed.25175364.s2.e0" text="vincristine" /><entity charOffset="179-184" id="DDI-PubMed.25175364.s2.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.25175364.s2.e0" e2="DDI-PubMed.25175364.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25175364.s2.e0" e2="DDI-PubMed.25175364.s2.e1" /></sentence><sentence text="" /><sentence text="A pharmacokinetic (PK) model for vincristine in children was used to simulate concentration-time profiles"><entity charOffset="33-44" id="DDI-PubMed.25175364.s4.e0" text="vincristine" /></sentence><sentence text=" A continuous model for body surface area versus age was defined based on pediatric growth curves" /><sentence text=" Informative sampling time windows were derived using D-optimal design" /><sentence text=" The CTS framework was used to different magnitudes of clearance inhibition (10%, 25%, or 40%), sample size (30-500), the impact of missing samples or sampling occasions, and the age distribution, on the power to detect a significant inhibition effect, and in addition, the relative estimation error (REE) of the interaction effect" /><sentence text="" /><sentence text="A minimum group specific sample size of 38 patients with a total sample size of 150 patients was required to detect a clearance inhibition effect of 40% with 80% power, while in the case of a lower effect of clearance inhibition, a substantially larger sample size was required" /><sentence text=" However, for the majority of re-estimated drug effects, the inhibition effect could be estimated precisely (REE &lt; 25%) in even smaller sample sizes and with lower effect sizes" /><sentence text="" /><sentence text="This work demonstrated the utility of CTS for the evaluation of PK clinical trial designs in the pediatric oncology population" /><sentence text="" /></document>